Stockscreener 앱 받기
0.2068
0.44%
0.0014
전일 마감가:
$0.2054
열려 있는:
$0.2
하루 거래량:
1.18M
Relative Volume:
0.07
시가총액:
$2.46M
수익:
-
순이익/손실:
$-11.53M
주가수익비율:
-0.0429
EPS:
-4.82
순현금흐름:
$-11.12M
1주 성능:
-15.03%
1개월 성능:
-8.35%
6개월 성능:
-76.15%
1년 성능:
-88.21%
1일 변동 폭
$0.20
$0.2098
1주일 범위
$0.20
$0.254
52주 변동 폭
$0.15
$3.10
프로세사 파마슈티컬스 Stock (PCSA) Company Profile
명칭
Processa Pharmaceuticals Inc
전화
443-776-3133
주소
7380 COCA COLA DRIVE, HANOVER
PCSA을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
PCSA
Processa Pharmaceuticals Inc
|
0.2068 | 5.56M | 0 | -11.53M | -11.12M | -4.82 |
|
VRTX
Vertex Pharmaceuticals Inc
|
468.37 | 119.76B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
555.59 | 59.14B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
317.61 | 41.40B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
570.88 | 32.96B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
278.00 | 26.46B | 3.81B | -644.79M | -669.77M | -6.24 |
프로세사 파마슈티컬스 Stock (PCSA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-04-25 | 개시 | H.C. Wainwright | Buy |
프로세사 파마슈티컬스 주식(PCSA)의 최신 뉴스
Processa Pharmaceuticals Reschedules Annual Shareholder Meeting - TipRanks
Processa Pharmaceuticals to reconvene annual meeting after achieving quorum - Investing.com
Why Processa Pharmaceuticals Inc. stock attracts strong analyst attentionCarefully Curated High Return Stocks - Newser
How Processa Pharmaceuticals Inc. stock performs during market volatility5x Profit Potential - Newser
What makes Processa Pharmaceuticals Inc. stock price move sharplyRisk Managed Trading Strategy - Newser
Processa Pharmaceuticals: Betting on Catalyst-Driven Value Acceleration - AInvest
Processa Pharmaceuticals, Inc. (PCSA) Secures Buy Rating on Portfolio Progress - Insider Monkey
Processa Stock Soars 33.96% on Penny Stock Inclusion - AInvest
12 Best Fundamentally Strong Penny Stocks to Invest in - Insider Monkey
HC Wainwright Has Positive Estimate for Heatwurx Q2 Earnings - Defense World
Processa terminates license agreement for PCS3117 - TipRanks
Heatwurx (NASDAQ:PCSA) Given New $2.00 Price Target at HC Wainwright - Defense World
Processa Pharmaceuticals adjourns annual meeting due to lack of quorum - Investing.com
Processa Pharmaceuticals adjourns annual meeting due to lack of quorum By Investing.com - Investing.com UK
Processa Pharmaceuticals Adjourns Annual Shareholder Meeting - TipRanks
Processa Pharmaceuticals Stock Soars 55.37% on Public Offering - AInvest
Processa Pharmaceuticals Announces Public Offering Pricing - TipRanks
Processa inks licensing deal with Intact for gastroparesis drug By Investing.com - Investing.com India
Processa Pharmaceuticals (PCSA) Sets Public Offering Price at $0 - GuruFocus
Processa Pharmaceuticals Signs Binding Term Sheet Granting - GlobeNewswire
Processa Pharmaceuticals (PCSA) Enters Licensing Agreement for G - GuruFocus
Processa Pharmaceuticals Prices of $7 Million Public Offering - citybiz
Processa inks licensing deal with Intact for gastroparesis drug - Investing.com
Processa Pharmaceuticals Announces Pricing of $7 Million Public Offering | PCSA Stock News - GuruFocus
Processa Pharmaceuticals (PCSA) Announces Public Offering Pricin - GuruFocus
Processa Pharmaceuticals Prices $7 Million Public Offering - MarketScreener
Processa Pares Gains on Equity Offer News - MarketWatch
Processa Pharmaceuticals (PCSA) Announces Public Offering Pricing | PCSA Stock News - GuruFocus
Processa sells 28M shares at 25c in public offering - TipRanks
Processa sees 28M shares at 25c in public offering - TipRanks
Processa Pharmaceuticals Announces Pricing of $7 Million Public Offering - GlobeNewswire
Processa Pharmaceuticals Secures $7M Funding: Next-Generation Cancer Drug Trial Gets Green Light - Stock Titan
Processa Pharmaceuticals Announces Licensing Deal with Intact - TipRanks
Processa Pharmaceuticals (PCSA) Shares Soar 150% On Gastroparesis Drug Deal - Benzinga
Processa Pharmaceuticals Grants Intact Therapeutics Exclusive Option to License Gastroparesis Drug Candidate; Shares Rise - marketscreener.com
Processa Pharmaceuticals Skyrockets on Game-Changing Gastroparesis Deal - RagingBull
Processa Pharmaceuticals signs binding term sheet with Intact Therapeutics - TipRanks
Processa Pharmaceuticals Signs Binding Term Sheet Granting Intact Therapeutics Exclusive Option to License Phase 2 Gastroparesis Drug Candidate - Yahoo Finance
Processa Pharmaceuticals (NASDAQ:PCSA) Trading Down 12.9% – Time to Sell? - Defense World
Navigating PCSA’s Stock Market Maze: Ups and Downs in 2023 - investchronicle.com
Processa Pharmaceuticals to Engage Potential Partners and Investors at BIO International Convention 2025 - GlobeNewswire
Processa Pharmaceuticals (PCSA) Prepares for Strategic Insights at BIO Convention 2025 | PCSA Stock News - GuruFocus
Processa to engage potential partners, investors at BIO International Convention - TipRanks
Processa Pharmaceuticals to Engage Potential Partners and Invest - GuruFocus
PCSA Stock Placement by H.C. Wainwright & Co. | PCSA Stock News - GuruFocus
Processa Pharmaceuticals to Showcase Next Generation Cancer Therapies at 2025 BIO International Convention - Nasdaq
Next-Gen Cancer Drug Developer Processa Pharma Eyes Strategic Partners at Major BIO Convention - Stock Titan
Pre-market Movers: NIVF, TRAW, KKR, AGEN... - RTTNews
Processa Pharmaceuticals presents cancer drug advances at ASCO By Investing.com - Investing.com South Africa
Processa Pharmaceuticals (PCSA) Highlights Cancer Drug Advances at ASCO 2025 | PCSA Stock News - GuruFocus
Processa Pharmaceuticals Announces Presentation and Publication - GuruFocus
프로세사 파마슈티컬스 (PCSA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
프로세사 파마슈티컬스 주식 (PCSA) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Ng George K | Chief Executive Officer |
Jan 27 '25 |
Buy |
0.80 |
87,200 |
69,542 |
87,200 |
| Young David | Pres. Research & Development |
Jan 27 '25 |
Buy |
0.80 |
124,500 |
99,289 |
205,405 |
| Lin Patrick | Chief Business - Strategy Off |
Jan 27 '25 |
Buy |
0.80 |
43,500 |
34,691 |
43,500 |
2.81%
1.62%
자본화:
|
볼륨(24시간):